Targets › HSV-TK
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2030.
Open in Phaseline: the race on HSV-TK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Methodist Hospital Research Institute | HSV-Tk Herpes simplex virus thymidine kinase gene therapy delivered by adenoviral vector to enhan | HSV-TK | Phase 2 | High-risk Prostate Cancer | – |
| Trogenix | TGX-007 AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing | HSV-TK, IL12 | Phase 1 | Glioblastoma (GBM) | Mar 2030 |
High-risk Prostate Cancer (1) Glioblastoma (GBM) (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.